AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28287054 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control group)
Number of subjects: 0
Study 26350343 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment with non-invasive tests plus invasive urodynamic testing (IUT)
Number of subjects: 222
Study 26350343 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment with non-invasive tests (control arm)
Number of subjects: 222
Study 23246229 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberine gelatin (5 mg/g) applied 4 times per day for 5 days
Number of subjects: 84
Study 23246229 — intervention group
Group type: COMPARATOR
Intervention: Placebo gelatin
Number of subjects: 84
Study 21413865 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement containing 12 vitamins and 9 minerals
Number of subjects: 91
Study 21413865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 19684155 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment for 12 months
Number of subjects: 60
Study 19684155 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment for nonresponders after 12 months of MTX
Number of subjects: 60
Study 19684155 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 15980646 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal termination
Number of subjects: 0
Study 15980646 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol termination
Number of subjects: 0
Study 15980646 — intervention group
Group type: COMPARATOR
Intervention: Intra-amniotic injection of prostaglandin termination
Number of subjects: 0
Study 12909504 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant FSH‐alpha (150 IU/day)
Number of subjects: 50
Study 12909504 — intervention group
Group type: COMPARATOR
Intervention: hMG (150 IU/day)
Number of subjects: 50
Study 12909504 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 50
Study 10560790 — intervention group
Group type: EXPERIMENTAL
Intervention: Single microbead diltiazem delivery system
Number of subjects: 40
Study 10560790 — intervention group
Group type: COMPARATOR
Intervention: Dual microbead diltiazem delivery system
Number of subjects: 40
Study 8712394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTFC)
Number of subjects: 90
Study 8712394 — intervention group
Group type: COMPARATOR
Intervention: Placebo oralet
Number of subjects: 90
Study 8712394 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 90
Study 8712394 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 90
Study 8712394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8712394 — intervention group
Group type: COMPARATOR
Intervention: OTFC, Placebo, Control
Number of subjects: 90
Study 2015974 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 1,5-anhydroglucitol (AG) levels
Number of subjects: 1620
Study 2015974 — intervention group
Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 1620
Study 2015974 — intervention group
Group type: COMPARATOR
Intervention: Fructosamine (FA)
Number of subjects: 1620
Study 2015974 — intervention group
Group type: EXPERIMENTAL
Intervention: AG and HbA1c together
Number of subjects: 1620
Study 6633618 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with trimethoprim/sulfamethoxazole (43 courses)
Number of subjects: 88
Study 6633618 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy with tobramycin (23 courses)
Number of subjects: 88
Study 6633618 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy to eradicate bacteriuria
Number of subjects: 88
Study 6633618 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 88
Study 6633618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality and infectious morbidity after randomization
Number of subjects: 88
Study 29952801 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme pump position
Number of subjects: 0
Study 29952801 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartMate II pump position at implant
Number of subjects: 0
Study 28145818 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education, diet supervision and exercise supervision (twice a week)
Number of subjects: 60
Study 28145818 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal lifestyle)
Number of subjects: 60
Study 26054185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrices containing 1.5% arginine, 1450 ppm fluoride as sodium monofluorophosphate (MFP), and an insoluble calcium compound (either dicalcium phosphate or calcium carbonate)
Number of subjects: 5500
Study 26054185 — intervention group
Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride as sodium fluoride (NaF)
Number of subjects: 5500
Study 23686738 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ibandronate (150 mg)
Number of subjects: 42
Study 23686738 — intervention group
Group type: COMPARATOR
Intervention: Weekly alendronate (70 mg)
Number of subjects: 42
Study 23686738 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 42
Study 21158903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia education programme (n=46)
Number of subjects: 102
Study 21158903 — intervention group
Group type: COMPARATOR
Intervention: Conventional stoma education programme (n=56)
Number of subjects: 102
Study 19572297 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium membrane
Number of subjects: 32
Study 19572297 — intervention group
Group type: COMPARATOR
Intervention: e-PTFE membrane
Number of subjects: 32
Study 19572297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Titanium and e-PTFE)
Number of subjects: 32
Study 17803060 — intervention group
Group type: EXPERIMENTAL
Intervention: Test drug (10 mg amlodipine tablet - Intervask)
Number of subjects: 12
Study 17803060 — intervention group
Group type: COMPARATOR
Intervention: Reference drug
Number of subjects: 12
Study 17803060 — intervention group
Group type: COMPARATOR
Intervention: Test drug vs Reference drug
Number of subjects: 12
Study 15780454 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic and syntactic processing evaluated on grammaticality judgement task
Number of subjects: 1
Study 15780454 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic and syntactic processing evaluated on sentence‐picture matching task
Number of subjects: 1
Study 12425551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (5 min on a treadmill at a 20% incline at 10 km/h)
Number of subjects: 12
Study 12425551 — intervention group
Group type: COMPARATOR
Intervention: Resting (control)
Number of subjects: 12
Study 10483844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT) with instructions to drop safety behaviours
Number of subjects: 30
Study 10483844 — intervention group
Group type: COMPARATOR
Intervention: Standard cognitive-behaviour therapy (CBT)
Number of subjects: 30
Study 8630576 — intervention group
Group type: EXPERIMENTAL
Intervention: FK‐888 (2.5 mg)
Number of subjects: 9
Study 8630576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1925965 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin and clindamycin
Number of subjects: 56
Study 1925965 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 56
Study 7049959 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (75 mg/kg body weight)
Number of subjects: 120
Study 7049959 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 120
Study 30707660 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX (gemcitabine 1,000 mg/m2 on day 1 and oxaliplatin 85 mg/m2 on day 2 of a 2-week cycle for 12 cycles)
Number of subjects: 196
Study 30707660 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (standard arm B)
Number of subjects: 196
Study 30707660 — intervention group
Group type: EXPERIMENTAL
Intervention: GEMOX
Number of subjects: 196
Study 30707660 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 196
Study 29530071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase (multidisciplinary team intervention)
Number of subjects: 1071
Study 29530071 — intervention group
Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 1071
Study 29530071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase
Number of subjects: 1071
Study 27265507 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 10 mg
Number of subjects: 1326
Study 27265507 — intervention group
Group type: EXPERIMENTAL
Intervention: empagliflozin 25 mg
Number of subjects: 1326
Study 27265507 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1326
Study 24493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic rehabilitation programme
Number of subjects: 52
Study 24493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring concentric strength at 60°/s
Number of subjects: 52
Study 24493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring concentric strength at 300°/s
Number of subjects: 52
Study 24493666 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstring eccentric strength
Number of subjects: 52
Study 24493666 — intervention group
Group type: COMPARATOR
Intervention: Players without reinjury (N=46)
Number of subjects: 52
Study 23031143 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring adherence
Number of subjects: 0
Study 23031143 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone visits adherence
Number of subjects: 0
Study 23031143 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of adherence
Number of subjects: 0
Study 23031143 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between telemonitoring and phone visits
Number of subjects: 0
Study 20576804 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure control goal of <130/80 mmHg
Number of subjects: 0
Study 20576804 — intervention group
Group type: COMPARATOR
Intervention: Observational data and secondary analyses
Number of subjects: 0
Study 17953922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% isotonic saline
Number of subjects: 71
Study 17953922 — intervention group
Group type: COMPARATOR
Intervention: 0.45% hypotonic saline
Number of subjects: 71
Study 17953922 — intervention group
Group type: EXPERIMENTAL
Intervention: Both isotonic and hypotonic saline
Number of subjects: 71
Study 16391723 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12413183 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interview (ACASI)
Number of subjects: 1142
Study 12413183 — intervention group
Group type: COMPARATOR
Intervention: Interviewer-administered questionnaires (IAQ)
Number of subjects: 1142
Study 9857596 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% phosphoric etching gel (pH 1) applied in the peri-implant sulcus
Number of subjects: 16
Study 9857596 — intervention group
Group type: COMPARATOR
Intervention: Control therapy with supra- and subgingival debridement using carbon fiber curettes and a rubber cup
Number of subjects: 16
Study 8730504 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 63
Study 8730504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 63
Study 8730504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined low antigen diet and therapy
Number of subjects: 63
Study 8730504 — intervention group
Group type: COMPARATOR
Intervention: Unrestrained diet
Number of subjects: 63
Study 2215608 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodiol
Number of subjects: 600
Study 2215608 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 600
Study 2215608 — intervention group
Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 600
Study 101263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early return to work (advised to return to work early)
Number of subjects: 295
Study 101263 — intervention group
Group type: COMPARATOR
Intervention: Standard return to work (supervised by general practitioner)
Number of subjects: 295
Study 101263 — intervention group
Group type: EXPERIMENTAL
Intervention: Early return to work
Number of subjects: 295
Study 101263 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss of earnings while off work
Number of subjects: 295
Study 101263 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic benefit of early return to work
Number of subjects: 295
Study 101263 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence rate at 1 year
Number of subjects: 295
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: High stressors
Number of subjects: 152
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: High resources
Number of subjects: 152
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: School stressors and resources
Number of subjects: 152
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: Friend stressors and resources
Number of subjects: 152
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: Family resources
Number of subjects: 152
Study 29617953 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe TBI
Number of subjects: 152
Study 26575180 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine lozenge
Number of subjects: 18
Study 26575180 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 18
Study 25102882 — intervention group
Group type: EXPERIMENTAL
Intervention: SLM deposition basal crowns
Number of subjects: 168
Study 25102882 — intervention group
Group type: COMPARATOR
Intervention: Cobalt chromium alloy casting base crowns
Number of subjects: 168
Study 23131885 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (up to 2400 mg/d)
Number of subjects: 48
Study 23131885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 20691553 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheolytic thrombectomy (RT) before direct stenting (DS)
Number of subjects: 501
Study 20691553 — intervention group
Group type: COMPARATOR
Intervention: Direct stenting (DS) alone
Number of subjects: 501
Study 18517289 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 99
Study 18517289 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 10 mg
Number of subjects: 99
Study 18517289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 15960563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg/day)
Number of subjects: 123
Study 15960563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123
Study 12949359 — intervention group
Group type: EXPERIMENTAL
Intervention: High sterol margarine (1.5 g/d plant sterols + 0.5 g/d plant stanols)
Number of subjects: 44
Study 12949359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sterol margarine (1 g/d plant sterols + 1 g/d plant stanols)
Number of subjects: 44
Study 12949359 — intervention group
Group type: COMPARATOR
Intervention: Control margarine
Number of subjects: 44
Study 12949359 — intervention group
Group type: EXPERIMENTAL
Intervention: High sterol margarine
Number of subjects: 44
Study 12949359 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sterol margarine
Number of subjects: 44
Study 12949359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both mixtures (high and low sterol margarines)
Number of subjects: 44
Study 10536548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask
Number of subjects: 25
Study 10536548 — intervention group
Group type: COMPARATOR
Intervention: Conventional laryngeal mask
Number of subjects: 25
Study 9735593 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative affectivity (NA)
Number of subjects: 97
Study 1867552 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol instillation in one eye
Number of subjects: 10
Study 1867552 — intervention group
Group type: COMPARATOR
Intervention: Fellow, untreated eye
Number of subjects: 10
Study 6417606 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 50
Study 30819227 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 96
Study 30819227 — intervention group
Group type: COMPARATOR
Intervention: Venturi mask oxygen therapy
Number of subjects: 96
Study 29727403 — intervention group
Group type: EXPERIMENTAL
Intervention: Breaking sitting (walking for 2 min every 20 min over 5.5 h)
Number of subjects: 11
Study 29727403 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting
Number of subjects: 11
Study 27511325 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 44
Study 27511325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24633056 — intervention group
Group type: EXPERIMENTAL
Intervention: UrgoClean dressing
Number of subjects: 159
Study 24633056 — intervention group
Group type: COMPARATOR
Intervention: Aquacel dressing
Number of subjects: 159
Study 22350834 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIO suturing device
Number of subjects: 50
Study 22350834 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture ligation
Number of subjects: 50
Study 20139767 — intervention group
Group type: EXPERIMENTAL
Intervention: Communicating APOE genotype and lifetime Alzheimer disease risk information
Number of subjects: 246
Study 18695911 — intervention group
Group type: EXPERIMENTAL
Intervention: p-STAT3 expression in invasive CRA
Number of subjects: 167
Study 18695911 — intervention group
Group type: EXPERIMENTAL
Intervention: p-STAT3 expression in invasive CRA determined by real-time PCR
Number of subjects: 167
Study 18695911 — intervention group
Group type: EXPERIMENTAL
Intervention: IHC analysis of p-STAT3 expression
Number of subjects: 167
Study 18695911 — intervention group
Group type: COMPARATOR
Intervention: IHC analysis of p-STAT3 expression in CRA vs adenoma and normal mucosae
Number of subjects: 167
Study 15944779 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU continuous infusion (320 mg/m2/day) for 14 days followed by oral HCFU (300 mg/day) for one year
Number of subjects: 429
Study 15944779 — intervention group
Group type: COMPARATOR
Intervention: 5-FU continuous infusion alone for 14 days
Number of subjects: 429
Study 12578919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy (HA)
Number of subjects: 142
Study 12578919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperintense T2 signal
Number of subjects: 142
Study 12578919 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractory FMTLE
Number of subjects: 142
Study 12578919 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of epilepsy
Number of subjects: 142
Study 10646729 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT) for 8 months
Number of subjects: 102
Study 10646729 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT) for allergy to mites
Number of subjects: 102
Study 10646729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 10646729 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific local nasal immunotherapy (LNIT)
Number of subjects: 102
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Working under harmful conditions during pregnancy (exposure to physical and/or chemical factors)
Number of subjects: 526
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued work under harmful conditions by the end of the second trimester
Number of subjects: 526
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to chemical factors
Number of subjects: 526
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to physical factors
Number of subjects: 526
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 526
Study 9312650 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's single status, smoking during pregnancy, poor health condition during pregnancy
Number of subjects: 526
Study 8354771 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 0
Study 8354771 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 8354771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3729199 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (6.5 and 13 micrograms/kg)
Number of subjects: 8
Study 3729199 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg, 30 minutes before breakfast)
Number of subjects: 8
Study 3729199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30407633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic canola oil supplemented with DHA (HOCO-DHA)
Number of subjects: 129
Study 30407633 — intervention group
Group type: COMPARATOR
Intervention: High-oleic canola oil (HOCO)
Number of subjects: 129
Study 28106573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle strengthening exercise integrated rTMS (group II)
Number of subjects: 30
Study 28106573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle strengthening exercise (group I)
Number of subjects: 30
Study 28106573 — intervention group
Group type: COMPARATOR
Intervention: rTMS (control group)
Number of subjects: 30
Study 26814458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine-1% thymol varnish
Number of subjects: 12
Study 26814458 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% fluoride varnish
Number of subjects: 12
Study 26814458 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 12
Study 24697031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with prostate cancer (CaP)
Number of subjects: 42
Study 24697031 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy men
Number of subjects: 42
Study 24697031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with low severity of CaP (T1)
Number of subjects: 42
Study 24697031 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with higher tumor stage (T2+T3+T4)
Number of subjects: 42
Study 22025997 — intervention group
Group type: EXPERIMENTAL
Intervention: OFD + OCHS (test)
Number of subjects: 30